Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2021 Earnings Conference Call November 3, 2021 8:30 AM ET Company Participants Jason Finkelstein - Argot Partners Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Senior Vice President-Sales & Commercial Operations Jatin Shah - Chief Medical Officer Mike Mason - Chief Financial Officer Stephen Mitchener - Chief Business Officer Sharon Shacham - Chief Scientific Officer Conference Call Participants Maury Raycroft - Jefferies Peter Lawson - Ba ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-393 ...

1 ©2021 KARYOPHARM THERAPEUTICS INC. A Commercial-Stage Pharmaceutical Company Pioneering Novel Cancer Therapies September 2021 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's guidance on its expected cash runway; expectations and plans relating to XPOVIO for the treatment of adult patients with relap ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 26-3931704 ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Joe Rayne - Argot Partners Richard Paulson - President & Chief Executive Officer Sohanya Cheng - Senior Vice President-Sales & Commercial Operations Jatin Shah - Chief Medical Officer Mike Mason - Chief Financial Officer Conference Call Participants Brian Abrams - RBC Capital Markets Peter Lawson - Barclays David Lebowitz - Morgan Stanley Eric Joseph - JPMorgan Jonathan Chang - SVB Leer ...

1 ©2021 KARYOPHARM THERAPEUTICS INC. August 5, 2021 Business Highlights & Second Quarter 2021 Financial Results On Today's Call • Welcome Joseph Rayne, Argot Partners • Overview Richard Paulson, President and Chief Executive Officer • Commercial Highlights Sohanya Cheng, SVP, Sales and Commercial Operations • Clinical Pipeline Updates Jatin Shah, MD, Chief Medical Officer • Financial Summary and Guidance Michael Mason, Chief Financial Officer • Closing Remarks Richard Paulson, President and Chief Executive ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 Karyopharm Therapeutics Inc. (Exact name of registrant as specified in its charter) (State or other jur ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2021 Results Earnings Conference Call May 3, 2021 8:30 AM ET Company Participants Ian Karp - Senior Vice President, Investor and Public Relations Richard Paulson - President and Chief Executive Officer Michael Kauffman - Co-Founder, Senior Clinical Advisor and Board Member Michael Mason - Chief Financial Officer John Demaree - Chief Commercial Officer Stephen Mitchener - Chief Business Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Mau ...

1 ©2021 KARYOPHARM THERAPEUTICS INC. Investor Conference Call: First Quarter 2021 Financial Results and Business Update May 3, 2021 On Today's Call Prepared Remarks • Michael G. Kauffman, MD, PhD, Co-Founder, Senior Clinical Advisor and Board Member • Mike Mason, MBA, Chief Financial Officer • Richard Paulson, MBA, President and Chief Executive Officer Joining for Q&A Session • John Demaree, MBA, Chief Commercial Officer • Sharon Shacham, PhD, MBA, Chief Scientific Officer • Stephen Mitchener, PharmD, Chief ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36167 KARYOPHARM THERAPEUTICS INC. Securities registered pursuant to Section 12(g) of the Act: None Indicate by chec ...